Literature DB >> 10739878

Modification of alternative splicing pathways as a potential approach to chemotherapy.

D Mercatante1, R Kole.   

Abstract

Many cancer-associated genes are alternatively spliced; their expression leads to the production of multiple splice variants. Although the functions of most of these variants are not well-defined, some have antagonistic activities related to regulated cell death mechanisms. In a number of cancers and cancer cell lines, the ratio of the splice variants is frequently shifted so that the anti-apoptotic splice variant predominates. This observation suggests that modification of splicing, which restores the proper ratio of alternatively spliced gene products, may reverse the malignant phenotype of the cells and offer a gene-specific form of anticancer chemotherapy. Our laboratory has extensively investigated the use of antisense oligonucleotides for shifting the splicing patterns of several genes. Potential application of this method for treatment of cancers, as well as of certain genetic disorders, is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739878     DOI: 10.1016/s0163-7258(99)00067-4

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  17 in total

1.  The contribution of exon-skipping events on chromosome 22 to protein coding diversity.

Authors:  W A Hide; V N Babenko; P A van Heusden; C Seoighe; J F Kelso
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

2.  Identification and characterization of syntaxin 1 antisense variants in Limulus polyphemus.

Authors:  Z Cao; Y Wang; B S McAdory; M D Kemp; M T Ivy; R F Newkirk; J G Townsel
Journal:  Cell Mol Neurobiol       Date:  2006-02       Impact factor: 5.046

3.  The small splice variant of HPV16 E6, E6, reduces tumor formation in cervical carcinoma xenografts.

Authors:  Maria Filippova; Whitney Evans; Robert Aragon; Valery Filippov; Vonetta M Williams; Linda Hong; Mark E Reeves; Penelope Duerksen-Hughes
Journal:  Virology       Date:  2014-01-01       Impact factor: 3.616

4.  Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy.

Authors:  Selwyn M Vickers; Zhi-Qiang Huang; LeeAnn MacMillan-Crow; Jessica S Greendorfer; John A Thompson
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

5.  A subtle alternative splicing event of the Na(V)1.8 voltage-gated sodium channel is conserved in human, rat, and mouse.

Authors:  Jana Schirmeyer; Karol Szafranski; Enrico Leipold; Christian Mawrin; Matthias Platzer; Stefan H Heinemann
Journal:  J Mol Neurosci       Date:  2009-12-02       Impact factor: 3.444

6.  Emetine regulates the alternative splicing of caspase 9 in tumor cells.

Authors:  Danmin Pan; Kritsanapol Boon-Unge; Piyarat Govitrapong; Jianhua Zhou
Journal:  Oncol Lett       Date:  2011-08-29       Impact factor: 2.967

7.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

8.  Large-scale evidence for conservation of NMD candidature across mammals.

Authors:  David A de Lima Morais; Paul M Harrison
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

9.  Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells.

Authors:  Janardhan Sampath; Pandy R Long; Robert L Shepard; Xiaoling Xia; Viswanath Devanarayan; George E Sandusky; William L Perry; Anne H Dantzig; Mark Williamson; Mark Rolfe; Robert E Moore
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism.

Authors:  Kritsanapol Boon-Unge; Qingming Yu; Tie Zou; An Zhou; Piyarat Govitrapong; Jianhua Zhou
Journal:  Chem Biol       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.